Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Size: px
Start display at page:

Download "Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI"

Transcription

1 Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri

2 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism Pregnancy complications

3 Virchow s Triad 1850 Vessel Wall Damage Factors Contributing to Thrombosis Altered Blood Flow (Stasis) Blood Coagulability

4 One or more Inherited Prothrombotic Mutation(s) Factor V Leiden Prothrombin 20210A Protein C deficiency Protein S deficiency Antithrombin deficiency Thrombosis After Schafer Acquired Prothrombotic Stimulus Antiphospholipid antibodies Malignancy Immobilization Surgery Pregnancy Estrogen Hyperhomocysteinemia Heparin-induced thrombocytopenia

5 Prevalence of Hereditary Risk Factors in Venous Thromboembolism (VTE) Asymptomatic Unselected Familial Mutation (N) Controls VTE VTE Factor V Leiden (1) 4% 20% 45% Prothrombin 20210A (1) 2% 6% 18% Protein C (>160) 0.8% 3% 6% Protein S (>13) 0.5% 1% 6% Antithrombin (>80) 0.2% 1% 4% (All Autosomal Dominant)

6 Factor V Leiden Most common hereditary risk factor for venous thrombosis Present in 4% of Caucasian population Caused by a point mutation in Factor V (R506Q) Poor anticoagulant response to activated protein C (APC Resistance)

7 The Protein C Anticoagulant Pathway Blood Flow Protein C Thrombin Thrombin Thrombomodulin APC Thrombus Thrombus at site of injury Anticoagulation downstream

8 The Protein C Anticoagulant Pathway Blood Flow Factor V Leiden Vai VIIIai APC PS Va VIIIa APC PS Thrombus

9 Activated Protein C Resistance 3 APTT Ratio 2 Control 1 Factor V Leiden APC (µg/ml)

10 Prothrombin Gene Mutation Second most common hereditary risk factor for venous thrombosis Present in 2% of Caucasian population Caused by a point mutation (G20210A) in the 3 UTR of prothrombin gene Elevated levels of prothrombin in plasma

11 Antithrombin Deficiency Antithrombin (also called AT III) inhibits thrombin, factor Xa and other clotting factors Activity enhanced by heparin Risk factor for venous thrombosis, especially during pregnancy

12 Influence of Hereditary Risk Factors on Probability of First DVT or PE Risk Factor Relative Risk General population 1 Heterozygous factor V Leiden 5 Heterozygous prothrombin 20210A 5 Protein C deficiency 10 Protein S deficiency 10 Antithrombin deficiency 20 Homozygous factor V Leiden 80

13 Influence of Hereditary Risk Factors on Probability of First DVT or PE Thrombosis-free Survival (%) 100 general population (RR=1) Age (years) heterozygous FVL (RR=5) protein C def (RR=10) antithrombin def (RR=20) homozygous FVL (RR=80) After Miletich (1998) Semin Thromb Hemost

14 Influence of Acquired Risk Factors on Probability of First DVT or PE Risk Factor Relative Risk General population 1 Hyperhomocysteinemia 2 Estrogen therapy 4 Active cancer ~7 Lupus anticoagulant or antiphospholipid antibody ~10

15 Hyperhomocysteinemia Elevated level of homocysteine in plasma Multiple causes Genetic factors uncommon Nutritional factors (folate, B12, B6) common Renal dysfunction common Cardiovascular disease, stroke, peripheral vascular disease Neural tube defects Dementia

16 Treatment of Hyperhomocysteinemia Folic acid Other B vitamins (B12, B6) Methionine restriction Foltx

17 Antiphospholipid Antibodies Lupus Anticoagulants Anticardiolipin Antibodies Clinically-Important APLA

18 Clinically Important Antiphospholipid Antibodies High titer (>30 GPL or MPL) anticardiolipin antibodies (IgG or IgM) Lupus anticoagulant Systemic lupus erythematosus or lupus-like syndrome

19 Management of Patients with Antiphospholipid Antibodies Chronic anticoagulation not necessary if no history of thrombosis Long-term anticoagulation with warfarin after first thrombotic event Target INR 2-3 (hematologists) Target INR 3-4 (rheumatologists) Some antiphospholipid antibodies interfere with INR (may need higher target INR or alternative method to monitor anticoagulation)

20 Influence of Combinations of Risk Factors on Probability of First DVT/PE Risk Factor Relative Risk General population 1 Hyperhomocysteinemia 2 Heterozygous factor V Leiden 5 Hyperhomocysteinemia and heterozygous factor V Leiden 20

21 Influence of Combinations of Risk actors on Probability of First DV or PE Risk Factor Relative Risk General population 1 Oral contraceptives 4 Heterozygous factor V Leiden 5 Oral contraceptives and heterozygous factor V Leiden 35

22 Influence of Oral Contraceptives nd Factor V Leiden on Probability of First DVT or PE Thrombosis-free Survival (%) 100 general population (RR=1) oral contraceptives (RR=4) pregnancy (RR=10) Age (years) oral contraceptives and heterozygous FVL (RR=35)

23 Hereditary Risk Factors and Arterial Thrombosis (Stroke or MI) Risk Factor Relative Risk Heterozygous Factor V Leiden 1 Heterozygous Prothrombin 20210A 1 Protein S deficiency 1 Protein C deficiency 1 Antithrombin deficiency 1 Possible exception: young patients, especially in association with smoking or hypertension

24 Other Putative Risk Factors (Not Ready for Prime Time) Fibrinogen Lipoprotein (a) Factor VIII Von Willebrand factor Thrombomodulin Heparin Cofactor II Factor XII GPIa C807T GPIIIa PLA2 PAI-1 4G/5G D-dimer TFPI MTHFR Protein Z

25 Laboratory Testing for Thrombophilia Factor V Leiden Prothrombin 20210A gene mutation Anticardiolipin antibodies Lupus anticoagulant workup Plasma total homocysteine Antithrombin (not reliable in patients receiving heparin)

26 Other Tests to Consider in Convalescent Period Protein C Protein S These tests are not reliable in acute setting or in patients receiving warfarin

27 Rationale for Thrombophilia Testing Prophylactic anticoagulation during high risk situations (surgery, pregnancy, immobilization) Extended duration of anticoagulation after a thrombotic event Antiphospholipid antibody Antithrombin deficiency Two or more thrombophilic alleles (Factor V Leiden, Prothrombin 20210A, Protein C deficiency, Protein S deficiency) Family genetic counseling

28 Probability of Recurrence After First DVT or PE Relative Risk Temporary risk factor 1 Heterozygous factor V Leiden 2 Homozygous factor V Leiden 4 Antiphospholipid antibody 4 Unprovoked DVT or PE 8 Recurrent DVT or PE 8 Active Cancer 8

29 Recurrence after First DVT or PE 30 Recurrent DVT/PE (%) warfarin unprovoked temporary risk factor Days Levine et al. Thromb Haemost 1995; 74:606

30 Duration of Anticoagulation for First Unprovoked DVT Recurrence (%) months (INR 2-3) 12 months (INR 2-3) Indefinite (INR 1.5-2) Indefinite (INR 2-3) Years

31 My Approach to Prevention of Recurrent Venous Thromboembolism Low Risk (anticoagulate for 6 weeks to 3 months) Superficial venous thrombosis Secondary DVT or PE Intermediate Risk (anticoagulate for at least 3 to 6 months; consider indefinite anticoagulation at INR or 2-3) Unprovoked DVT or PE Unprovoked DVT or PE with one genetic risk factor High Risk (anticoagulate indefinitely at target INR 2-3) Recurrent unprovoked DVT or PE Life-threatening venous thrombosis Unprovoked DVT or PE with antiphospholipid antibody, two or more genetic risk factors, or active cancer

32 References Kearon et al. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 51: , 2000 Kupferminc, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. New Eng J Med 340:9-13, 1999 Gerhardt, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the peurperium. New Eng J Med 342: , 2000 Gordy et al. American College of Medical Genetics Consensus Statement on Factor V Leiden mutation testing. Genetics in Medicine 3: , 2001 Ridker et al. Long-term low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. New Eng J Med 348: , 2003 Lopez et al. Deep venous thrombosis. American Society of Hematology Education Book, 2004

Thrombosis. By Dr. Sara Mohamed Abuelgasim

Thrombosis. By Dr. Sara Mohamed Abuelgasim Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood

More information

Laboratory Evaluation of Venous Thrombosis Risk

Laboratory Evaluation of Venous Thrombosis Risk Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic

More information

Thrombophilia: To test or not to test

Thrombophilia: To test or not to test Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical

More information

Are there still any valid indications for thrombophilia screening in DVT?

Are there still any valid indications for thrombophilia screening in DVT? Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016

More information

Approach to Thrombosis

Approach to Thrombosis Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation

More information

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?

More information

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase

More information

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis

More information

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)

More information

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective

More information

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels

More information

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine Scott M. Stevens, MD Co-Director, Thrombosis Clinic Intermountain Medical Center Associate Professor of Clinical Medicine The University of Utah School of Medicine No Relevant Financial Relationships Research

More information

COAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION

COAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION LABORATORY DIAGNOSIS OF PROTHROMBOTIC COAGULATION INHIBITORS Tissue Factor Pathway Inhibitor (TFPI) Lipoprotein Associated Coagulation Inhibitor (LACI) Extrinsic Pathway Inhibitor (EPI) Complexes with

More information

Should Patients with Venous Thromboembolism Be Screened for Thrombophilia?

Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability

More information

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures

More information

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota Disclosures Financial interests

More information

THROMBOPHILIA SCREENING

THROMBOPHILIA SCREENING THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis

More information

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital

More information

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic

More information

Optimal Utilization of Thrombophilia Testing

Optimal Utilization of Thrombophilia Testing Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine

More information

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the

More information

Molecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer

Molecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer Molecular mechanisms & clinical consequences of prothrombin mutations A.J. Hauer 07-12-2018 Prothrombin & the coagulation cascade Coagulation factor II, thrombin. Prothrombin is synthesized in the liver

More information

The Multi-Factorial Threshold Model of Thrombotic Risk

The Multi-Factorial Threshold Model of Thrombotic Risk The Multi-Factorial Threshold Model of Thrombotic Risk Richard A. Marlar, PhD and Dorothy M. Adcock, MD The incidence of venous thrombosis in the US is between two and three million per year, resulting

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

Thrombophilias: A Practical Approach

Thrombophilias: A Practical Approach Disclosures Thrombophilias: A Practical Approach Speaker s Bureau: BMS/Pfizer (Apixaban) PI Altru Health System: EVE Trial Apixaban in Malignancy Keith E Swanson MD North Dakota Family Medicine Conference,

More information

Potpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy

Potpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Potpourri of Hematology Oncology Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Lifestyle Modifications to Decrease the Risk of Colorectal Cancer Estimates for 2018 American

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

Original Policy Date

Original Policy Date MP 2.04.71 Genetic Testing for Inherited Thrombophilia Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search12:2013 Return to

More information

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer

More information

Faculty Disclosure. Hypercoagulable States. Learning Objectives. Hereditary Thombophilia. Acquired Hypercoagulable States 5/9/2016

Faculty Disclosure. Hypercoagulable States. Learning Objectives. Hereditary Thombophilia. Acquired Hypercoagulable States 5/9/2016 Faculty Disclosure Hypercoagulable States Dr. Rizal has no actual or potential conflict of interest associated with this presentation By: Dr. Anuja Rizal Pharm. D., RPh., CACP Clinical Coordinator UConn

More information

Venous thromboembolism (VTE) consists of deep vein

Venous thromboembolism (VTE) consists of deep vein Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders Richard D. Press, MD, PhD; Kenneth A. Bauer, MD; Jody L. Kujovich, MD; John A. Heit, MD

More information

Predicting the risk of recurrent venous thromboembolism (VTE)

Predicting the risk of recurrent venous thromboembolism (VTE) J Thromb Thrombolysis (2015) 39:353 366 DOI 10.1007/s19-015-1188-4 Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business

More information

THROMBOTIC DISORDERS: The Final Frontier

THROMBOTIC DISORDERS: The Final Frontier THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.

More information

Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD

Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH TO T HROMBOPHILIA W ORKUPS & FRESH F ROZEN P LASMA U SE Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Learning Objectives AFTER COMPLETION

More information

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism

More information

Sinus and Cerebral Vein Thrombosis

Sinus and Cerebral Vein Thrombosis Sinus and Cerebral Vein Thrombosis A Summary Sinus and cerebral vein clots are uncommon. They can lead to severe headaches, confusion, and stroke-like symptoms. They may lead to bleeding into the surrounding

More information

Genetics of Arterial and Venous Thrombosis: Clinical Aspects and a Look to the Future

Genetics of Arterial and Venous Thrombosis: Clinical Aspects and a Look to the Future Genetics of Arterial and Venous Thrombosis: Clinical Aspects and a Look to the Future Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular

More information

Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD

Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Thrombosis II Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Inherited Risk Factors for Venous Thrombosis Mary Cushman Venous

More information

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)

More information

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE

More information

Cancer and venous thromboembolism

Cancer and venous thromboembolism Journal of BUON 10: 483-489, 2005 2005 Zerbinis Medical Publications. Printed in Greece REVIEW ARTICLE Cancer and venous thromboembolism J. Grudeva-Popova Department of Hematology, University Hospital

More information

Diagnosis and management of heritable thrombophilias

Diagnosis and management of heritable thrombophilias Link to this article online for CPD/CME credits Diagnosis and management of heritable thrombophilias Peter MacCallum, 1 2 Louise Bowles, 2 David Keeling 3 1 Wolfson Institute of Preventive Medicine, Barts

More information

Low-Molecular-Weight Heparin

Low-Molecular-Weight Heparin Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs

More information

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior

More information

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior

More information

Arterial Ischemic Stroke with Protein S Deficiency in Pakistan

Arterial Ischemic Stroke with Protein S Deficiency in Pakistan Case Reports Arterial Ischemic Stroke with Protein S Deficiency in Pakistan Faika Usman, Ali Hassan, Arsalan Ahmad From Section of Neurology, Department of Medicine, Shifa International Hospitals and College

More information

Chapter 1 Introduction

Chapter 1 Introduction Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep

More information

Laboratory Markers in the Diagnosis of Venous Thromboembolism

Laboratory Markers in the Diagnosis of Venous Thromboembolism Laboratory Markers in the Diagnosis of Venous Thromboembolism Joseph A. Caprini, MD, Catherine J. Glase, BS, Christopher B. Anderson, Karen Hathaway, BS Department of Surgery Evanston Northwestern Healthcare,

More information

Recurrent Venous Thrombo-Embolism in a Young Adult Female: Case Report with Review of Literature

Recurrent Venous Thrombo-Embolism in a Young Adult Female: Case Report with Review of Literature Cronicon OPEN ACCESS CARDIOLOGY Case Report Recurrent Venous Thrombo-Embolism in a Young Adult Female: Case Report with Review of Literature Ehab M Esheiba 1 *, Ani Purushothaman 2 1 Departments of Cardiology,

More information

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis

More information

THROMBOSIS RISK FACTOR ASSESSMENT

THROMBOSIS RISK FACTOR ASSESSMENT Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)

More information

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis

More information

Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE

More information

Pulmonary Thromboembolism

Pulmonary Thromboembolism Pulmonary Thromboembolism James Allen, MD Epidemiology of Pulmonary Embolism 1,500,000 new cases per year in the United States Often asymptomatic 300,000 deaths per year DVT or PE present in 10% of ICU

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

Menopausal Hormone Therapy & Haemostasis

Menopausal Hormone Therapy & Haemostasis Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen

More information

In which direction, and how aggressively,

In which direction, and how aggressively, Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Evaluating idiopathic venous thromboembolism: What is necessary, what is not Charles F. S. Locke, MD Johns Hopkins Community

More information

Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A.

Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A. Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data Kenneth A. Bauer, MD kbauer@bidmc.harvard.edu Disclosures Janssen rivaroxaban BMS apixaban Boehringer

More information

Annals of RSCB Vol. XVII, Issue 1/2012

Annals of RSCB Vol. XVII, Issue 1/2012 CORRELATIONS BETWEEN ENDOTHELIAL DYSFUNCTION AND GLYCEMIA IN VENOUS THROMBOSIS PATHOGENESIS Codruţa Bădescu 1, Oana Bădulescu 2, Manuela Ciocoiu 2, Magda Bădescu 2, M. Costuleanu 2 1 DEPARTMENT OF INTERNAL

More information

This chapter will describe the effectiveness of antithrombotic

This chapter will describe the effectiveness of antithrombotic Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,

More information

CHAPTER 2 VENOUS THROMBOEMBOLISM

CHAPTER 2 VENOUS THROMBOEMBOLISM CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology

More information

CADTH. August [Draft] Draft for Consultation 1

CADTH. August [Draft] Draft for Consultation 1 CADTH August 2014 [Draft] Effectiveness of Factor V Leiden and Prothrombin Mutation Testing in Patients Presenting with Unprovoked First Thromboembolic Episode: Systematic Review and Economic Analysis

More information

Hypercoagulable State

Hypercoagulable State 1 1 4 Hypercoagulable State Andrew I. Schafer The Concept of Hypercoagulability................ 2423 Primary Hypercoagulable States.................. 2426 Secondary Hypercoagulable States................

More information

Thrombophilia due to Activated Protein C Resistance

Thrombophilia due to Activated Protein C Resistance CASE REPORT JIACM 2005; 6(3): 244-7 Thrombophilia due to Activated Protein C Resistance Kamal S Saini*, Mrinal M Patnaik*, Vidya S Nagar**, Alaka K Deshpande*** Abstract Thrombophilia is a hereditary or

More information

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH How to cite this article: CHOWTA NITHYANANDA K, ARUN S, BIPIN P, FAZIL A. CHRONIC THROMBOEMBOLIC PULMONARY ARTERY HYPERTENSION WITH DEEP VEIN THROMBOSIS DUE

More information

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be

More information

Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden

Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Inaugural meeting of Iranian Society on Thrombosis and Haemostasis Mofid Children Hospital Tehran, 24 December 2015 Chest. 2012;141(2_suppl):e48S-e801S

More information

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital

More information

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy: Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division

More information

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005 Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

Thrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD

Thrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD Thrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD Corresponding author Stephan Moll, MD Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine, CB7035,

More information

Testing for genetic predisposition to venous thrombosis

Testing for genetic predisposition to venous thrombosis Testing for genetic predisposition to venous thrombosis By Marisa B. Marques, M.D. CONTINUING EDUCATION To earn CEUs, see test on page 20. LEARNING OBJECTIVES Upon completion of this article the reader

More information

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal

More information

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D.

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Bleeding disorders von Willebrand disease Hemophilia A and B DIC TTP/HUS ITP Thrombotic disorders Factor V Leiden

More information

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March

More information

Duration of Anticoagulation: Applying the Guidelines and Beyond

Duration of Anticoagulation: Applying the Guidelines and Beyond ISSUES IN THROMBOSIS MANAGEMENT AND ANTICOAGULATION Duration of Anticoagulation: Applying the Guidelines and Beyond Kenneth A. Bauer 1,2 1 Hematology Section, VA Boston Healthcare System and Beth Israel

More information

PE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management

PE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management PE service Regional College Lecture PE Management Update in medicine (Eastern) Cambridge 29 th June 2017 Dr Rachel M Limbrey DM FRCP University Hospital Southampton NHS Foundation Trust Ambulatory acute

More information

Thrombosis. Jeffrey Jhang, M.D.

Thrombosis. Jeffrey Jhang, M.D. Thrombosis Jeffrey Jhang, M.D. Introduction The human hemostatic system has evolved to maintain blood flow under normal physiologic conditions while remaining primed to rapidly respond to vascular injury

More information

Thrombophilia testing in patients with venous thrombosis

Thrombophilia testing in patients with venous thrombosis Thrombophilia testing in patients with venous thrombosis Joseph A. Caprini, MD, Sofia Goldshteyn, MD, Catherine J. Glase, BS, Karen Hathaway, BS, Evanston and Chicago, IL. Department of Surgery Evanston

More information

Acute Pulmonary Embolism and Deep Vein Thrombosis. Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center COPYRIGHT

Acute Pulmonary Embolism and Deep Vein Thrombosis. Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center COPYRIGHT Acute Pulmonary Embolism and Deep Vein Thrombosis Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center Acute PE and DVT No disclosures. Acute PE and DVT Learning objectives

More information

Is Thrombophilia Testing Useful?

Is Thrombophilia Testing Useful? CONSULTATIVE HEMATOLOGY I: COMMON QUESTIONS IN THROMBOSIS CONSULTS Is Thrombophilia Testing Useful? Saskia Middeldorp 1 1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

More information

ARTICLE IN PRESS. Thrombophilia Testing in Patients with Venous Thrombosis. Feinberg School of Medicine, Chicago, IL, USA UNCORRECTED PROOF

ARTICLE IN PRESS. Thrombophilia Testing in Patients with Venous Thrombosis. Feinberg School of Medicine, Chicago, IL, USA UNCORRECTED PROOF Eur J Vasc Endovasc Surg xx, 1 6 (xxxx) doi:10.1016/j.ejvs.2005.05.034, available online at http://www.sciencedirect.com on 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

More information

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get

More information

How long to continue anticoagulation after DVT?

How long to continue anticoagulation after DVT? How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in

More information

CLINICAL FELLOWSHIP PROGRAM IN COAGULATION

CLINICAL FELLOWSHIP PROGRAM IN COAGULATION CLINICAL FELLOWSHIP PROGRAM IN COAGULATION The Department of Pathology and Laboratory Medicine University of Alberta, Faculty of Medicine and Dentistry and Alberta Health Services CLINICAL FELLOWSHIP IN

More information

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired

More information

Hyperhomocysteinemia, Deep Vein Thrombosis and Vitamin B12 Deficiency in a Metformin-treated Diabetic Patient

Hyperhomocysteinemia, Deep Vein Thrombosis and Vitamin B12 Deficiency in a Metformin-treated Diabetic Patient CASE REPORT Hyperhomocysteinemia, Deep Vein Thrombosis and Vitamin B12 Deficiency in a Metformin-treated Diabetic Patient Hsuan-Yu Lin, 1 Chih-Yuan Chung, 1 Cheng-Shyong Chang, 1 Ming-Lun Wang, 1 Jen-Shiou

More information

COAGULATION AND TRANSFUSION MEDICINE Review Article. A Laboratory Approach to the Evaluation

COAGULATION AND TRANSFUSION MEDICINE Review Article. A Laboratory Approach to the Evaluation COAGULATION AN TRANSFUSION MEICINE Review Article A Laboratory Approach to the Evaluation of Hereditary Hypercoagulability OROTHY M. ACOCK, M, 1-2 LOUIS FINK, M, 3 AN RICHAR A. MARLAR, Ph 2 ' 4 The concept

More information

Lipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation

Lipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation Patient: SAMPLE PATIENT DOB: Sex: MRN: 3701 CV Health Plus Genomics - Plasma, Serum & Buccal Swab Methodology: Chemiluminescent, Enzymatic, Immunoturbidimetric, NMR and PCR Lipid Markers Cholesterol LDL-

More information

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical

More information

Hematologic Disorders. Assistant professor of anesthesia

Hematologic Disorders. Assistant professor of anesthesia Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's

More information

Duration of anticoagulation

Duration of anticoagulation Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,

More information

PE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP

PE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP PE and DVT Dr Anzo William Adiga WatsApp or Call +256777363201 Medical Officer/RHEMA MEDICAL GROUP OBJECTIVES DEFINE DVT AND P.E PATHOPHYSIOLOGY OF DVT CLINICAL PRESENTATION OF DVT/PE INVESTIGATE DVT MANAGEMENT

More information

Prevalence of Activated Protein C Resistance in Acute Myocardial Infarction in Japan

Prevalence of Activated Protein C Resistance in Acute Myocardial Infarction in Japan Clinical Studies Prevalence of Activated Protein C Resistance in Acute Myocardial Infarction in Japan Kazunori HAYASHI, MD, Takahito SONE,1 MD, Junichiro KONDOH,1 MD, Hideyuki TSUBOI,1 MD, Hiromi SASSA,1

More information

Combined Factor V Leiden and Prothrombin Genotyping in Patients Presenting With Thromboembolic Episodes

Combined Factor V Leiden and Prothrombin Genotyping in Patients Presenting With Thromboembolic Episodes Combined Factor V Leiden and Prothrombin Genotyping in Patients Presenting With Thromboembolic Episodes John A. Friedline, MD; Ejaz Ahmad, MD; Diana Garcia, MD; Deborah Blue, MD; Noel Ceniza, MD; Joan

More information

VTE in Children and Adolescents: Epidemiology and Special Considerations for Therapy

VTE in Children and Adolescents: Epidemiology and Special Considerations for Therapy VTE in Children and Adolescents: Epidemiology and Special Considerations for Therapy Ellis J. Neufeld MD, PhD Associate Chief, Division of Hematology/Oncology Boston Children s Hospital and Dana Farber

More information

VENOUS THROMBOEMBOLISM

VENOUS THROMBOEMBOLISM VENOUS THROMBOEMBOLISM Parker Truong, D.O. Interventional Cardiology Oklahoma Heart Hospital Physicians RELEVANT DISCLOSURE Under the Oklahoma State Medical Association CME guidelines disclosure must be

More information